"Portfolio empowerment" is one of the core principles that HLC consistently upholds in the pursuit of our mission and goals. It drives technological innovation and deepens industry understanding. It is also an essential part of HLC’s talent development strategy.

Recently, HLC team, along with our portfolio companies and ecosystem partners, embarked on a 5-day business development trip to Thailand and Indonesia. This event not only continued to empower the portfolio companies within the HLC ecosystem, but also further strengthened our investment presence in Southeast Asia, while opening up new collaborative opportunities for the portfolio companies to expand into the Southeast Asian market.

Thailand Trip:

The team visited leading CDMO and clinical CRO companies in Thailand, as well as biopharmaceutical companies, and engaged in in-depth discussions on areas such as product line collaboration, product approval and registration, and channel partnerships. Additionally, the group toured the largest public and private hospitals in the region, including Ramathibodi Hospital and Bumrungrad Hospital, where initial agreements were reached on local medical needs and potential clinical collaborations.

At the Asia Industrial Park and the Eastern Economic Corridor, key representatives introduced HLC team to local government policies, favorable business environment, established infrastructure, and tax incentives available in the region. Furthermore, two of Thailand's largest banks provided tailored strategic solutions to the delegation members regarding financial services.

Indonesia Trip:

HLC team arrived first at HLC’s biopharmaceutical portfolios in Indonesia, Etana and UBC, where they engaged in in-depth discussions. These companies have demonstrated significant local leadership in the fields of biologics, active pharmaceutical ingredient (API) production, and in vitro diagnostics (IVD). Through interactions between teams and site visits to the factories and laboratories, portfolios from HLC’s ecosystem gained a deeper understanding of their respective business developments and technological innovations, further reinforcing their confidence and potential for expansion in Indonesia and the broader Southeast Asian market.

The visit also involves high-level meetings with Indonesia's Ministry of Health, BPOM (National Agency of Drug and Food Control), and industry associations for pharmaceuticals and medical devices. Discussions covered policy trends, market opportunities, and regulatory requirements in Indonesia's healthcare sector, laying a solid foundation for future business expansion and policy engagement in the country.

HLC team also visited the leading public hospital Siloam, where they engaged in detailed discussions with the hospital management on medical equipment needs, operational models, patient services, and technological innovations.

This Southeast Asia trip not only reinforced HLC’s confidence in existing investments but also strengthened trust and support through interactions with the governments and healthcare sectors in both local governments. HLC is determined to continue supporting the development of Southeast Asia's healthcare industry, empowering our portfolios and contributing to the creation of an innovative and sustainable health ecosystem.